ArticleNPJ vaccines2021
A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice.
Article in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Human vaccines & immunotherapeutics · 2026Review
- Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice.NPJ vaccines · 2025Article
- Fabrication of Microneedles by Pulsating In Situ Dried Electrostretching for Transdermal Drug Delivery.Small methods · 2025Article
- Serum-Free Suspension Culture of theViruses · 2025Article
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- Insect-specific virus platforms for arbovirus vaccine development.Frontiers in immunology · 2025Review
- Insect-specific viruses: transmission dynamics and biological control strategies against arboviruses.Frontiers in microbiology · 2025Review
- A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge.NPJ vaccines · 2024Article
- Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine.Vaccines · 2024Article
- Article
- Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine.Molecular therapy. Nucleic acids · 2023Article
- Review
- A chimeric vaccine protects farmed saltwater crocodiles from West Nile virus-induced skin lesions.NPJ vaccines · 2023Article
- Proceedings of the 5th Asia Dengue Summit.Tropical medicine and infectious disease · 2023Article
- A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement.Frontiers in immunology · 2023Article
- Skin-patch delivered subunit vaccine induces broadly neutralising antibodies against SARS-CoV-2 variants of concern.Vaccine · 2022Article
- Engineering carbon nanotubes for sensitive viral detection.Trends in analytical chemistry : TRAC · 2022Review
- Reporter Flaviviruses as Tools to Demonstrate Homologous and Heterologous Superinfection Exclusion.Viruses · 2022Article
- Local Response and Barrier Recovery in Elderly Skin Following the Application of High-Density Microarray Patches.Vaccines · 2022Article
- Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Dengue viruses (DENV) cause an estimated 390 million infections globally. With no dengue-specific therapeutic treatment currently available, vaccination is the most promising strategy for its control. A wide range of DENV vaccines are in development, with one having already been licensed, albeit with limited distribution. We investigated the immunogenicity and protective efficacy of a chimeric virus vaccine candidate based on the insect-specific flavivirus, Binjari virus (BinJV), displaying the structural prM/E proteins of DENV (BinJ/DENV2-prME). In this study, we immunized AG129 mice with BinJ/DENV2-prME via a needle-free, high-density microarray patch (HD-MAP) delivery system. Immunization with a single, 1 µg dose of BinJ/DENV2-prME delivered via the HD-MAPs resulted in enhanced kinetics of neutralizing antibody induction when compared to needle delivery and complete protection against mortality upon virus challenge in the AG129 DENV mouse model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.